Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer
โ Scribed by Dimitrios N. Melegos; Eleftherios P. Diamandis
- Publisher
- Elsevier Science
- Year
- 1996
- Tongue
- English
- Weight
- 578 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0009-9120
No coin nor oath required. For personal study only.
โฆ Synopsis
Objectives:
To examine the diagnostic value of prostate-specific antigen (psa) subfractions in the serum of female breast cancer patients.
Design and methods:
Psa subfractions (free psa, f-psa; psa bound to alpha 1-antichymotrypsin, psa-act) were determined in the serum of patients with breast cancer and in the serum of healthy women. serum was injected into a high-performance liquid chromatography column and all fractions were analyzed for psa using a highly sensitive psa immunofluorometric assay. we studied 3 normal male sera, 3 sera from prostate cancer patients who underwent radical prostatectomy (all for comparative purposes), 3 sera from healthy women, 3 sera from women with breast cancer obtained presurgically, and 7 sera from women with breast cancer, postsurgically.
Results:
All male sera contained mostly psa-act complexes and very little free psa. sera from all healthy women also contained mostly psa-act complexes and nondetectable or traces of free psa. all 3 presurgical sera from patients with breast cancer contained predominantly free psa. patients who had surgical resection of the breast tumor and were in remission had postsurgical serum psa subfractions similar to those of healthy women (i.e., mostly psa-act complexes).
Conclusion:
The serum psa subfractions of breast cancer patients are substantially different from serum psa subfractions of male patients, healthy females, and females who have apparently been treated successfully for breast cancer. these findings may form the basis for a serological diagnostic test for breast cancer.
๐ SIMILAR VOLUMES
We have analyzed matched serum and breast cyst fluid samples for total PSA from 148 patients with fibrocystic breast disease. We have also determined the molecular forms of PSA (free PSA and PSA bound to a 1 -antichymotrypsin) in 78 breast cyst fluid samples. We found that total PSA can be detected
Molecular forms of prostate-specific antigen (PSA) improve the differentiation between benign prostatic hyperplasia (BPH) and prostate cancer (PCa) in men with total PSA concentrations between 4 and 10 microg/l. To evaluate the diagnostic utility of free PSA (fPSA) and complexed PSA forms for identi
Prostatic-specific antigen (PSA) is regarded as a specific marker secreted by normal and neoplastic acinar epithelial cells of the prostate gland; its detection by immunocytochemistry has been accepted as an indication of metastatic prostate cancer. This is ascribed to the commonly held belief that
Background. The serum kinetics of prostate-specific antigen (PSA) after radiation therapy for prostate cancer are not well characterized, and the potential prognostic significance of serum half-lives and of serum doubling times is unclear. This study was designed to address those issues. Methods. O